AR100209A1 - Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos - Google Patents
Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicosInfo
- Publication number
- AR100209A1 AR100209A1 ARP150101268A ARP150101268A AR100209A1 AR 100209 A1 AR100209 A1 AR 100209A1 AR P150101268 A ARP150101268 A AR P150101268A AR P150101268 A ARP150101268 A AR P150101268A AR 100209 A1 AR100209 A1 AR 100209A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- halogen
- treatment
- substituted
- glyt1
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 title 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 title 1
- 230000002489 hematologic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 229940123454 Glucose transporter 1 inhibitor Drugs 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000023661 Haematological disease Diseases 0.000 abstract 1
- 208000033981 Hereditary haemochromatosis Diseases 0.000 abstract 1
- 206010065973 Iron Overload Diseases 0.000 abstract 1
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 abstract 1
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 abstract 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Son inhibidores de GlyT1, para su uso en el tratamiento de trastornos hematológicos, en particular, para su uso en el tratamiento de enfermedad de células falciformes y talasemia, o para el tratamiento de pacientes con síndromes de sobrecarga de hierro, tales como la hemocromatosis hereditaria. Reivindicación 5: Un inhibidor de GlyT1 de acuerdo con una cualquiera de las reivindicaciones 1 - 4, en el que el inhibidor de GlyT1 se selecciona de un compuesto de fórmula (1) en los que R¹ es halógeno, alquilo inferior sustituido con halógeno, ciano o S(O)₂-alquilo inferior; R² es alquilo inferior, alquilo inferior sustituido con halógeno o es (CH₂)ₒ-cicloalquilo; R³ es alquilo inferior, NH₂ o amino sustituido con uno o dos alquilos inferiores; X C o N; n es 1 ó 2; o es 0, 1 ó 2; así como sales de adición de ácido farmacéuticamente aceptables del mismo; o es un compuesto de fórmula (2) en el que R¹ es halógeno, alquilo inferior, alquilo inferior sustituido con halógeno, alcoxi, ciano o S(O)₂-alquilo inferior; R² es alquilo inferior, alquilo inferior sustituido con halógeno o es (CH₂)ₒ-cicloalquilo; R³ es alquilo inferior, NH₂ o amino sustituido con uno o dos alquilos inferiores; X es C o N; X¹ es C o N; en el que solo uno de X y X¹ es N; n es 1 ó 2; o es 0, 1 ó 2; así como sales de adición de ácido farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166497 | 2014-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100209A1 true AR100209A1 (es) | 2016-09-21 |
Family
ID=50677958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101268A AR100209A1 (es) | 2014-04-30 | 2015-04-28 | Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9877963B2 (es) |
| EP (1) | EP3137073B1 (es) |
| JP (1) | JP6283766B2 (es) |
| KR (1) | KR101869185B1 (es) |
| CN (1) | CN106163520B (es) |
| AR (1) | AR100209A1 (es) |
| CY (1) | CY1120508T1 (es) |
| ES (1) | ES2683184T3 (es) |
| HR (1) | HRP20181205T1 (es) |
| MA (1) | MA39927B1 (es) |
| MY (1) | MY189930A (es) |
| PH (1) | PH12016501784A1 (es) |
| PT (1) | PT3137073T (es) |
| RS (1) | RS57535B1 (es) |
| SG (2) | SG11201608397UA (es) |
| SI (1) | SI3137073T1 (es) |
| TR (1) | TR201809598T4 (es) |
| WO (1) | WO2015165842A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3199156A1 (de) * | 2016-02-01 | 2017-08-02 | Heinrich-Heine-Universität Düsseldorf | Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika |
| CU20200106A7 (es) * | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
| CN115279372A (zh) * | 2020-01-09 | 2022-11-01 | 迪斯克医药公司 | 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
| WO2022192731A1 (en) * | 2021-03-12 | 2022-09-15 | Disc Medicine, Inc. | Compositions and methods for treating anemia associated with a ribosomal disorder |
| JP2024518091A (ja) * | 2021-05-14 | 2024-04-24 | ディスク・メディシン・インコーポレイテッド | グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
| JP2024520391A (ja) * | 2021-05-27 | 2024-05-24 | ディスク・メディシン・インコーポレイテッド | ビトペルチンの固体形態を用いて赤血球増殖性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
| WO2023235326A1 (en) * | 2022-05-31 | 2023-12-07 | Disc Medicine, Inc. | Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00116B (me) * | 2003-08-11 | 2010-10-10 | Hoffmann La Roche | Piperazin sa ili supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| RS51204B (sr) * | 2005-02-07 | 2010-12-31 | F. Hoffmann-La Roche Ag. | Heterociklični supstituisani fenil metanoni kao inhibitori glicin transportera 1 |
-
2015
- 2015-04-27 SG SG11201608397UA patent/SG11201608397UA/en unknown
- 2015-04-27 CN CN201580016721.4A patent/CN106163520B/zh active Active
- 2015-04-27 RS RS20180897A patent/RS57535B1/sr unknown
- 2015-04-27 SI SI201530334T patent/SI3137073T1/sl unknown
- 2015-04-27 SG SG10201909382U patent/SG10201909382UA/en unknown
- 2015-04-27 TR TR2018/09598T patent/TR201809598T4/tr unknown
- 2015-04-27 MA MA39927A patent/MA39927B1/fr unknown
- 2015-04-27 ES ES15717916.9T patent/ES2683184T3/es active Active
- 2015-04-27 EP EP15717916.9A patent/EP3137073B1/en active Active
- 2015-04-27 JP JP2017505724A patent/JP6283766B2/ja active Active
- 2015-04-27 MY MYPI2016001545A patent/MY189930A/en unknown
- 2015-04-27 KR KR1020167030222A patent/KR101869185B1/ko active IP Right Grant
- 2015-04-27 PT PT157179169T patent/PT3137073T/pt unknown
- 2015-04-27 WO PCT/EP2015/059037 patent/WO2015165842A1/en active Application Filing
- 2015-04-28 AR ARP150101268A patent/AR100209A1/es not_active Application Discontinuation
-
2016
- 2016-09-13 PH PH12016501784A patent/PH12016501784A1/en unknown
- 2016-10-26 US US15/334,722 patent/US9877963B2/en active Active
-
2018
- 2018-07-25 HR HRP20181205TT patent/HRP20181205T1/hr unknown
- 2018-08-06 CY CY20181100809T patent/CY1120508T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101869185B1 (ko) | 2018-06-19 |
| CN106163520A (zh) | 2016-11-23 |
| US20170042888A1 (en) | 2017-02-16 |
| MA39927B1 (fr) | 2018-09-28 |
| MA39927A (fr) | 2017-03-08 |
| SG11201608397UA (en) | 2016-11-29 |
| MY189930A (en) | 2022-03-22 |
| EP3137073A1 (en) | 2017-03-08 |
| EP3137073B1 (en) | 2018-06-06 |
| ES2683184T3 (es) | 2018-09-25 |
| KR20160130517A (ko) | 2016-11-11 |
| CN106163520B (zh) | 2019-12-13 |
| CY1120508T1 (el) | 2019-07-10 |
| PH12016501784B1 (en) | 2016-11-07 |
| RS57535B1 (sr) | 2018-10-31 |
| JP6283766B2 (ja) | 2018-02-21 |
| SI3137073T1 (sl) | 2018-09-28 |
| WO2015165842A1 (en) | 2015-11-05 |
| TR201809598T4 (tr) | 2018-07-23 |
| SG10201909382UA (en) | 2019-11-28 |
| PT3137073T (pt) | 2018-07-27 |
| JP2017511385A (ja) | 2017-04-20 |
| HRP20181205T1 (hr) | 2018-09-21 |
| US9877963B2 (en) | 2018-01-30 |
| PH12016501784A1 (en) | 2016-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100209A1 (es) | Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| EA201790202A1 (ru) | Фталазиноны и изохинолиноны в качестве ингибиторов rock | |
| CR20150045A (es) | Inhibidores de hepatitis c | |
| EA201690989A1 (ru) | Ингибиторы syk | |
| TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. | |
| ECSP13013074A (es) | Nuevos derivados de piridina | |
| CR20150447A (es) | Nuevos derivados de pirazol | |
| EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| DOP2014000016A (es) | Indazoles novedosos inhibidores de janus quinasa | |
| CO7350652A2 (es) | Piridina-2-amidas útiles como agonistas de cb2 | |
| EA201490596A1 (ru) | Новые производные дигидрохинолин-2-она | |
| EA201690598A1 (ru) | Аминогетероарил бензамиды в качестве ингибиторов киназы | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201592182A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201190227A1 (ru) | Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ | |
| NI201200192A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica. | |
| RS54526B1 (en) | USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS | |
| EA201490912A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
| EA201400333A1 (ru) | Бензонитрильные производные в качестве ингибиторов киназ | |
| EA201490567A1 (ru) | Новые бициклические производные дигидрохинолин-2-она | |
| CR20150204A (es) | Nuevos derivados de piridina | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |